Connect with us

Survector (amineptine)


Amineptine (or SURVECTOR®) was mainly prescribed to treat major depressive disorder.

Status: DISCONTINUED

Class: Atypical, Tricyclic (TCA)

FDA Approval: International Only (Europe)

Dosage Forms: N/A

Biological Half-life: 0.8-1 hour

Side Effects: Dizziness, blurred vision, dry mouth, nausea, constipation, appetite changes, hyperhidrosis, sex drive changes

Routes of Administration: Oral

Pregnancy Category: N/A

  www.fda.gov

Like Us

Advertisement
Advertisement